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SHORT ABSTRACT: 
Novel therapeutic strategies in cardiac regenerative medicine require extensive and detailed 
studies in large preclinical animal models before they can be considered for use in humans. 
Here, we demonstrate a percutaneous contrast echocardiography-guided intramyocardial 
injection technique in rabbits, which is valuable for hypothesis testing the efficacy of such 
novel therapies. 
 
LONG ABSTRACT: 
Cell and gene therapy are exciting and promising strategies for the purpose of cardiac 
regeneration in the setting of heart failure with reduced ejection fraction (HFrEF). Before 
they can be considered for use, and implemented in humans, extensive preclinical studies 
are required in large animal models to evaluate the safety, efficacy, and fate of the injectate 
(e.g., stem cells) once delivered into the myocardium. Small rodent models offer advantages 
(e.g., cost effectiveness, amenability for genetic manipulation); however, given inherent 
limitations of these models, the findings in these rarely translate into the clinic. Conversely, 
large animal models such as rabbits, have advantages (e.g., similar cardiac electrophysiology 
compared to humans and other large animals), whilst retaining a good cost-effective 
balance. Here, we demonstrate how to perform a percutaneous contrast echocardiography-
guided intramyocardial injection (IMI) technique, which is minimally invasive, safe, well 
tolerated, and very effective in the targeted delivery of injectates, including cells, into 
several locations within the myocardium of a rabbit model. For the implementation of this 
technique, we also have taken advantage of a widely available clinical echocardiography 
system. After putting in practice the protocol described here, a researcher with basic 
ultrasound knowledge will become competent in the performance of this versatile and 
minimally invasive technique for routine use in experiments, aimed at hypothesis testing of 
the capabilities of cardiac regenerative therapeutics in the rabbit model. Once competency 
is achieved, the whole procedure can be performed within 25 min after anaesthetizing the 
rabbit.  
 
INTRODUCTION: 
Cell and gene therapies are exciting and ever developing strategies for 
regenerating/repairing the injured myocardium in HFrEF. A few studies have compared the 
effectiveness (e.g., cell retention rate) of the different routes of cell delivery, which have 
consistently demonstrated the superiority of IMI over intracoronary or intravenous routes1-
5. Thus, it is not surprising that a large proportion of studies on translational models of stem 
cell therapy of the injured myocardium, deliver the injectate via IMI performed under direct 
view in an open chest procedure6,7. However, this approach has several limitations, 
including the invasive nature of the procedure, which carries the risk of peri-procedural 
mortality (often under-reported)8. In addition, an IMI under direct view does not eliminate 
the possibility for inadvertent injection into the ventricular cavity. In clinical practice an IMI 
during open chest surgery could be an appropriate method for therapeutic cell delivery, 
e.g., during coronary artery bypass graft surgery (CABG); however, this approach may not be 
appropriate for cell delivery in global cardiomyopathy of non-ischemic origin (e.g., HFrEF 
secondary to anthracycline-induced cardiomyopathy (AICM)). 
 
There is no doubt that ischemic heart disease (IHD) is the most common cause of HFrEF (~ 
66%)9,10; however, non-ischemic cardiomyopathy, including AICM, still affects a significant 
proportion of patients with HFrEF (33%)9. Indeed, recent advances in clinical oncology have 
resulted in more than 10 million survivors of cancer in the USA alone11, with estimates of a 
similar number in Europe, consistent with an overall trend towards improved survival of 
cancer patients12,13. Thus, exploring the benefits of novel therapies such as stem cell 
transplant for non-ischemic cardiomyopathy, as well as the trialing of an effective and 
minimally invasive route of stem cell delivery is of utmost importance, given the increasing 
number of patients affected by cardiotoxicity secondary to anticancer drugs. 
 
Of note, hypothesis testing studies using stem cell therapy aiming to repair/regenerate the 
injured myocardium frequently involves the use of small rodents (e.g., mice and rats). These 
models often require expensive high frequency ultrasound systems for evaluation of 
myocardial function, usually equipped with linear array transducers which have some 
inherent associated limitations (e.g., reverberation)14. However, other models such as 
rabbits, representing a large preclinical model, have some advantages for hypothesis testing 
of stem cell therapies in HFrEF. Thus, in contrast to rats and mice, rabbits maintain a Ca+2 
transport system and cellular electrophysiology that resembles that of humans and other 
large animals (e.g., dogs and pigs)15-19. Another advantage, is their amenability for cardiac 
ultrasound imaging using relatively inexpensive and widely available clinical 
echocardiography systems equipped with relatively high frequency phase array transducers, 
e.g., 12 MHz, such as those frequently used in neonatal and pediatric cardiology. These 
systems allow excellent echocardiographic imaging with state of the art technology, and 
they take advantage of the superiority of harmonic imaging20. Furthermore, extensive 
hypothesis testing of the potential of cardiac regenerative therapies (e.g., stem cell 
therapy), their safety, efficacy, cardiomyogenic potential, as well as evaluation of the fate of 
the injectate once delivered into the myocardium, is mandatory before they can be 
considered for human use, and they require the use of large preclinical animal models, such 
as the rabbit17,19. Here, we describe a minimally invasive technique for cell delivery via 
percutaneous contrast-echocardiography guided IMI using a clinical echocardiography 
system, which is aimed at stem cell transplant-based therapy for non-ischemic 
cardiomyopathy20. We also describe the benefits of India Ink (InI, also known as China Ink) 
as an ultrasound contrast agent and in situ tracer of the injectate in the rabbit heart. 
 
PROTOCOL:  
 
The experiments described herein were approved by the Ethical Research Committee of the 
University of Murcia, Spain, and were performed in accordance with Directive 2010/63/EU 
of the European Commission. The steps described were performed under standard 
operating protocols that were part of the plan of work and have not been performed solely 
for the purpose of filming the accompanying video to this paper. 
 
1. Preparation of Cells and Mammalian Expression Vector 
 
Note: Here, we briefly describe a protocol for preparation and transfection of a cell line 
(human embryonic kidney 293 (HEK-293)); however, appropriate cell specific protocols for 
the cell type of interest should be optimized (e.g., stem cells). 
 
1.1. Maintain HEK-293 cells in high glucose Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum (FCS), 1% sodium pyruvate, 2 mM Glutamine, 1% 
penicillin/streptomycin, and incubated at 37 °C in a humidified atmosphere containing 5% 
CO2. Once cells are sub-confluent, split at a ratio of 1:3.  
 
1.2. Start splitting the cells by aspirating the media, then wash once with sterile 
phosphate buffered saline (PBS), remove excess PBS and then incubate with 2.5 mL of 0.5x 
Trypsin-Ethylenediaminetetraacetic acid (EDTA) (5 min, 37 °C).  
 
1.2.1. Add one volume of DMEM media (supplemented as described above) to stop the 
reaction, and then detach the cells by slowly and gently aspirating up and down with an 
electronic pipette.  
 
1.3. Then, transfer the cell suspension to an appropriate container (e.g., 15–50 mL 
conical centrifuge tube). Centrifuge in a swing bucket (100 x g), discard the supernatant and 
wash the pellet twice with sterile PBS.  
 
1.4. Resuspend the pellet in fresh DMEM media and seed at an appropriate cell density 
(e.g., 1 x 106 cells in a 75 cm2 flask) in fresh culture flasks or large dishes according to local 
laboratory practices.  
 
1.4.1. Replace existing media with fresh media every 2 days. 
 
Note: The expression vector was derived from pIRES1hyg and used according to the 
manufacturer’s instructions as previously described21. p(EGFP) IRES1hyg was generated by 
subcloning EGFP cDNA as a BamHI + NotI insert from pEGFP-N1 into the BamHI + NotI 
digested pIRES1hyg21.  
 
1.5. 1 day before transfection, seed HEK-293 cells at a density of 0.5 x 105 cells/cm2 in 12- 
or 24-well tissue culture plates.  
 
1.6. On the day of transfection, prepare DNA-lipid transfection reagent complexes in 
separate 1.5 mL microcentrifuge tubes (1 tube/well).  
 
1.6.1. Start by adding 250 µL of reduced serum medium into each tube, and then add 4 µg 
DNA (mix gently).  
 
1.6.2. Subsequently, add 250 µL from a previously prepared mix of 10 µL lipid transfection 
reagent and 250 µL of reduced serum medium, to each tube (mix again gently).  
 
1.6.3. Finally, proceed with transfections, by incubating HEK-293 cells with DNA lipid 
transfection reagent complexes for 4 h, and then replace with DMEM medium 
supplemented as described above (step 1.1), and incubate for another 48 h. Perform drug 
selection of stable transfectants with 100 μg/mL hygromycin B. 
 
1.7. Detach HEK-293 cells with trypsin as described above (step 1.2). After washing the 
cells in sterile PBS, resuspend in an appropriate vehicle (e.g., 10% v/v InI in PBS), to achieve 
a final cell concentration of 5 x 106/mL.  
 
2. Preparation of the Rabbit 
 
Note: The positioning of the rabbit and the transducer for IMI is not optimal to evaluate 
morphology and function of the heart of the animal. Thus, it is advisable to perform a 
complete echocardiographic examination20 prior to the IMI (see below), and at subsequent 
time points as defined by the experimental design. This will aim to evaluate the baseline 
anatomical and functional characteristics of the heart in the animal that will receive an 
injection, and also evaluate the effects, of IMI in the function of the heart.  
 
2.1. Perform this examination in a blinded fashion and following the guidelines of the 
Echocardiography Committee of the American College of Veterinary Internal Medicine and 
the American Society of Echocardiography/European Association for Cardiovascular 
Imaging22-24.  
 
2.2. Obtain a simultaneous 1-lead electrocardiogram (ECG) tracing throughout the whole 
echocardiographic study.  
 
2.3. Anesthetize the rabbit with ketamine 10 mg/kg, combined with medetomidine 200 
µg/kg, intramuscular (I.M.) injection. 
 
2.4. Verify the level of anesthesia after 10–20 min following administration of anesthesia.  
 
2.5. Using a hair clipper remove the hair of the chest widely (e.g., below the neck to the 
sub-xiphoid region) (Figure 1A).  
 
2.6. Shave additional regions of 1–2 cm2 in the internal face of the right forelimb 
(mediocubital region) and of both hind limbs (mediotibial region) (Figure 1B). 
 
2.7. Place adhesive ECG electrodes on the shaved regions of the limbs to synchronously 
monitor the heart rhythm during the procedure (Figure 1C).  
 
2.8. Place the animal in the decubitus supine position on a thermal blanket, with the 
limbs outstretched using surgical tape attached to the table (Figure 1C).  
 
2.8.1. Make sure the ears are flexed backwards behind the head/back of the rabbit, and at 
a position that is lower than its forelimbs, since this helps to maintain correct positioning of 
the thorax of the animal throughout the procedure. 
 
2.9. Allow the animal to breathe spontaneously whilst administering oxygen by face 
mask throughout the whole procedure (100%, 2–3 L/min). 
 
 
 
Figure 1. Preparation of the rabbit for IMI. (A) Clip hair from thorax; (B) Clip hair from 
limbs; (C) Attach electrodes and position the rabbit with legs outstretched on a thermal 
blanket. 
 
 
3. Percutaneous Contrast Echocardiography-guided IMI Technique in the Rabbit 
 
3.1. Clean and disinfect the skin of the thorax with a chlorhexidine-based solution.  
 
3.1.1.  Use an aseptic technique throughout the whole procedure, according to current 
best practice.  
 
3.1.2. Whenever possible, and if reasonably practicable, perform a fully sterile procedure, 
including, but not limited to, the use of sterile material such as gowns, gloves, surgical 
wound drapes, sterile dressing material for the table, as well as a sterile ultrasound 
transducer cover and sterile ultrasound gel. This will reduce to a minimum the risk of 
introducing pathogens to the animal receiving IMI, and is standard practice in the clinical 
setting (e.g., during cardiac puncture).  
 
Note: It is recommended to always proceed in line with local and national regulations of 
animal research applicable to the local institution and country of practice. 
 
3.2. Apply ultrasound transmission gel to the chest and/or to the transducer, and with 
the transducer cord around the experimenter’s neck, perform a quick window scan of the 
animal’s heart, which is often helpful to visualize anatomy and to plan for the IMI.  
 
3.3. Place the transducer manually at the 4th–6th intercostal space, 2–3 cm away from the 
right parasternal line with an angle of incidence of ~ 90° with respect to the right side of the 
thoracic wall (Figure 2A).  
 
3.4. Adjust the location of the transducer relative to the intercostal space as well as its 
anteroposterior and dorsoventral angle to optimize a modified short axis view at the level of 
the papillary muscles. Identify in this view the right ventricle (RV), left ventricle (LV), 
interventricular septum (IVS), posterior wall (PW), as well as anterolateral (AL) and 
posteromedial (PM) papillary muscles (Figure 2B).  
 
3.4.1. Have a wide field of view by significantly increasing the depth using the appropriate 
control on the system (e.g., button, dial).  
 
3.4.2. Pay particular attention to obtaining a symmetrical image in this view, as well as 
appropriate differentiation of endocardial and epicardial contours, and, if necessary, adjust 
through image optimization controls (e.g., gain). 
 
3.5. Once the optimal echocardiographic view is obtained (Figure 2B), maintain this 
position throughout the rest of the procedure, whilst a second operator performs the IMI 
(see below).  
 
3.5.1. Whilst holding the transducer, avoid concealing the transducer orientation mark, 
which should always be facing forward, thus allowing its alignment with the needle in 
subsequent steps (Figure 2A, C). 
 
3.6. With a 24-G needle attached to a 1 mL syringe, place the needle close to the skin of 
the left hemithorax in a symmetric mirroring position with respect to the transducer. Then, 
manually align the needle with the transducer orientation mark at an angle of ~ 90° (Figure 
2C), and slowly advance the needle through the skin and into the chest cavity.  
 
Note: The percutaneous needle insertion in this position and orientation facilitates the 
visualization of the needle in the plane of the ultrasound beam (Figure 2D, E), thus allowing 
real time monitoring and, when necessary, adjustment of the location of the needle relative 
to the target region of the myocardium (Figure 2G, H). 
 
3.7. With the tip at the target location, slowly deliver the injectate (up to 0.25 mL per 
injection site) within 10–30 s (Figure 2E), whilst slowly and gently retracting the needle 
during injection to increase the extent of the myocardium treated.  
 
3.7.1.  Use InI 10% (v/v) diluted in PBS for standardization of the technique, and as an in 
situ tracer whilst acquiring competency, as well as to confirm successful targeting of all four 
IMI sites within the myocardium by gross pathology and histopathology (see Representative 
Results). Once competency is achieved, InI could be substituted by a suitable commercial 
ultrasound contrast agent if desired.  
 
Note: Delivery of 10% (v/v) InI diluted in PBS either with or without cells into the 
myocardium results in transmural hyperechogenicity (i.e., echo bright appearance) at the 
target site of injection (Figure 2E, F). Transient deceleration or acceleration of the heart 
rate, associated with premature ventricular contractions (e.g., isolated, couplets and 
triplets) are frequently observed even from the first contact of the needle with the 
epicardium as well as during and/or shortly after IMI. However, no life-threatening 
arrhythmias are developed, and acute adverse effects are rarely observed using up to 0.25 
mL (1.25 x 106 cells) of injectate per IMI injection site (see Representative Results and 
Discussion). 
 
3.8. Perform subtle changes in the angle of incidence of the needle as necessary to 
complete injections of 0.25 mL to each of the four target IMI sites (three in the left 
ventricular free wall (LVFW) and one in the IVS).  
 
3.9. After completing the percutaneous contrast echocardiography-guided IMI 
procedure, evaluate heart rhythm (e.g., through serial ECG trace and/or 24 h Holter ECG), 
and perform serial window echocardiographic scans to verify the absence of complications, 
until the animal is fully recovered from anesthesia, and only then transfer to a light cycle 
room.  
 
3.9.1. Here, we use 24 h Holter ECG to monitor the effects of IMI with InI on heart rhythm 
for 24 h. For this, we compared a group of 6 rabbits with normal phenotype (Normal Group) 
and a group of 6 rabbits that received intravenous administration of Doxorubicin (a 
cardiotoxic anthracycline drug, commonly used for the treatment of cancer; DOX group) at a 
dose of 2 mg/kg/week for 8 weeks, and then both cohorts received IMI with InI. 
 
 
 
Figure 2. Percutaneous contrast echocardiography-guided intramyocardial injection in the 
rabbit. (A) Placement of the transducer in the right hemithorax at an angle of ~ 90°. (B) 
Representative image of a parasternal short axis view (PSSX) of the heart at the level of 
papillary muscles in the rabbit. (C) Alignment of the needle at an angle of ~ 90° relative to 
the transducer orientation mark. (D) Location of the needle at the target site in a PSSX view 
of the heart (note that the needle is easily visualized in the plane of the ultrasound beam). 
(E and F) Demonstration of hyperechogenicity at the target site upon intramyocardial 
injection with India Ink (arrowheads highlight the transmural hyperechogenicity). (G) 
Accidental location of the needle in the LV chamber (arrowheads highlight the needle shaft). 
(H) Repositioning of the needle to the LV free wall (arrowheads highlight the needle shaft). 
RV = right ventricle; LV = left ventricle; IVS = interventricular septum; PW = posterior wall; 
AL = anterolateral papillary muscle; PM = posteromedial papillary muscle. 
 
 
 
4. Post IMI Analyses 
 
4.1. Perform histopathological analysis of heart tissue samples from rabbits. 
 
4.1.1. Fix tissue for 24 h in 10% formaldehyde, followed by dehydration with increasing 
ethanol concentrations as follows: 
 1x in 70% (60 min) 
 1x in 95% ethanol/5% methanol (60 min) 
 1x in 100% (60 min) 
 2x in 100% (90 min) 
 1x in 100% (120 min) 
 
Note: All the above incubations are conducted at room temperature (RT). Then, substitute 
twice with 100% xylene (1 h, RT), and finally embed in paraffin in two steps (60 min, 58 
°C)25.  
 
4.1.2. Perform 4–5 μm tissue sections with a microtome25. Mount sections on slides. 
 
4.1.3. Perform staining with hematoxylin-eosin and Masson’s trichrome methods25-27. 
 
4.2. In tissue sections from transplanted hearts, perform immunohistochemistry to 
detect EGFP(+) HEK-293 cells (e.g., using the avidin-biotin complex (ABC) method), briefly: 
 
4.2.1. De-wax 4–5 µm thick heart sections in 100% xylene (10 min, at RT). Rehydrate tissue 
by washing with decreasing ethanol concentration solutions (2x in 100% (2 min); 2x in 95% 
(2 min); 1x in 70% (2 min); 1x in 50% (2 min); 1x in 30% (2 min); 1x ddH2O (2 min)) at RT. 
 
4.2.2. Perform endogenous peroxidase inhibition by covering the sections with 100 µL of 
3% H2O2 diluted in methanol (prepared with 5 mL of 30% stock solution of H2O2, and adding 
methanol up to a total volume of 50 mL) (incubate 30 min, RT), and then wash by immersion 
with Tris buffered saline (TBS; pH 7.6). 
 
4.2.3. Perform antigen unmasking via enzymatic treatment, by covering the sections with 
100 µL of 0.1% Pronase (prepared with 0.01 g Pronase diluted in 10 mL TBS) (incubate 12 
min, RT), then wash with TBS (5 min, RT). 
 
4.2.4. Incubate in blocking solution (normal goat serum at 10% in TBS) using 100 µL per 
slide (30 min, RT), and wash with TBS (5 min, RT). 
 
4.2.5. Incubate with chicken anti-green florescent protein (GFP) as primary antibody (1:500 
in TBS) (1 h, 30 °C), and wash with TBS (5 min, RT). 
 
4.2.6. Incubate with secondary antibody biotinylated goat-anti-chicken IgG (1:250 in TBS) 
(1 h, 30 °C), and then wash with TBS (5 min, RT). 
 
4.2.7. Incubate with avidin-biotin complex (20 min, 30 °C), and then label using 3,30-
diaminobenzidine tetrahydrochloride (DAB) (RT, 5–10 min). 
 
4.2.8. Finally, dehydrate by washing in increasing ethanol concentrations (1x in 30% (2 
min); 1x in 50% (2 min); 1x in 70% (2 min); 2x in 95% (2 min); 2x in 100% (2 min)) at RT, 
counterstain sections using the hematoxylin-eosin method25, and then mount cover slides. 
Include positive, negative as well as isotype controls.  
 
Note: The brief protocol described above is not intended for general immunohistochemistry 
use; optimization for the tissue of interest and conditions is necessary.  
 
REPRESENTATIVE RESULTS: 
 
Percutaneous Contrast Echocardiography-guided IMI with InI: 
 
Using the protocol described above, and once the optimal positioning of the tip of the 
needle was confirmed by echocardiography and the injection initiated, transmural 
hyperechogenicity was observed during the delivery of InI (10% v/v in PBS) (Figure 2E), as 
well as shortly after the IMI to the target region (Figure 2F). When IMI was immediately 
followed by euthanasia and the heart removed, deposits of InI were easily visible upon 
external examination of the heart (Figure 3A). In addition, heart tissue sections, e.g., short 
axis section at the level of the papillary muscles (Figure 3B), revealed transmural deposits of 
InI dye at the injection site, thus demonstrating the successful and effective delivery of 
injectate into the myocardium using this technique. Of note, the transmural 
hyperechogenicity observed in vivo during IMI (Figure 2E, F), correlated well with 
transmural deposits of InI in ex vivo specimens (Figure 3A, B). This clearly demonstrated 
that InI has dual properties in the setting of IMI: as an in vivo ultrasound contrast agent, as 
well as an ex vivo in situ tracer. Both of these properties make InI a very versatile and 
inexpensive ultrasound contrast agent, particularly for training during the acquisition of 
competency in this technique. Thus, the echogenic properties of InI help to monitor IMI e.g., 
determine successful IMI versus accidental intra-chamber or pericardial space injection, 
and, when necessary, given the real-time imaging capabilities of ultrasound, to make 
corrections of the needle track in real time (Figure 2G, H). On the other hand, the in situ 
tracing capabilities of InI are of value to locate the injectate in ex vivo specimens of the 
target myocardium.  
  
Percutaneous Contrast Echocardiography-guided IMI with InI and EGFP(+) HEK-293 Cells: 
 
Prior to IMI, successful transfection of EGFP(+) HEK-293 cells was confirmed by fluorescence 
microscopy during in vitro culture conditions (Figure 3C). The successful delivery of EGFP(+) 
HEK-293 cells into the myocardium was demonstrated via immunohistochemistry analysis of 
heart tissue sections where InI deposits were observed. Thus, using the avidin-biotin 
complex method (see step 4.2), abundant EGFP(+) HEK-293 cells were identified within the 
myocardium interspersed with InI deposits (Figure 3D). Deposits of InI were still observed 
24 h after IMI in myocardial tissue samples from rabbits that received either InI in 
combination with EGFP(+) HEK-293 cells (Figure 3E), or InI alone (Figure 3F). Of note, an 
acute inflammatory response was observed at this time point, with a predominant 
neutrophilic infiltrate, in samples from animals receiving EGFP(+) HEK-293 cells (Figure 3E), 
thus suggesting acute cellular rejection. On the other hand, macrophages were observed in 
animals receiving InI alone (Figure 3F).  
 
 
 
Figure 3. In situ macroscopic and histopathological evaluation and tracing of injectate. (A) 
Demonstration of the presence of injectate on external examination of an excised heart 
following IMI with InI (arrowheads highlight the sites of injection). (B) Demonstration of 
transmural distribution of injectate following IMI with InI in a transverse section of the heart 
at the level of the papillary muscles (blue arrowheads highlight the transmural InI deposit; 
white arrow highlights a visible deposit of InI at the IVS). (C) Autofluorescence in vitro of 
EGFP(+) HEK-293 cells using fluorescence microscopy. (D–F) Histopathological analysis of 
injected sites. EGFP(+) cells are visibly interspersed with InI deposits within the myocardium 
at 0 h (D) and 24 h (E) post IMI (blue arrowheads highlight EGFP(+) cells; red arrows 
highlight the presence of neutrophils). Deposits of InI interspersed within the myocardium 
at 24 h (F) following IMI with InI alone (blue arrows highlight the presence of macrophages). 
RV = right ventricle; LV = left ventricle; IVS = interventricular septum; IMI = Intramyocardial 
injection; InI = India Ink. 
Having performed over 60 percutaneous contrast echocardiography-guided IMI procedures 
to date, we believe that with careful attention to detail and good animal handling and care, 
the procedure is generally well tolerated, and acute complications are very rare and usually 
mild. In general, in animals that undergo IMI, the most frequent observation during and 
shortly after the procedure is transient acceleration or deceleration of heart rate, associated 
with isolated premature ventricular complexes (PVC) (Figure 4A). Thus, 24 h Holter ECG 
monitoring of animals that received InI alone via IMI, revealed that the most frequent 
arrhythmia detected (total number of episodes within 24 h) was isolated PVC, even though 
a higher number of episodes were detected in animals that were previously treated with 
DOX for 8 weeks (Figure 5A). PVC in couplets and triplets appear to be less frequent (Figure 
4B, C and Figure 5B, C), even though triplets are significantly less frequent in DOX-treated 
than in untreated Normal rabbits (Figure 5C). On the other hand, non-sustained ventricular 
tachycardia (NSVT) was more frequently observed in Normal animals (Figure 4D and Figure 
5D). Significantly, whilst the mean heart rate was not different between DOX and Normal 
groups after receiving IMI with InI alone (Figure 5E), the standard deviation of normal R-R 
interval (SDNN), was significantly reduced (< 100 ms) in the DOX group (Figure 5F). The 
SDNN is a non-linear measure of heart health status, and therefore this result indicates that 
the DOX group has global alterations in its cardiac physiological status. 
 
 
 
Figure 4. Ventricular arrhythmias observed during 24 h Holter monitoring in Rabbits that 
received IMI with InI. The images shown are screenshots obtained from Holter ECG 
tachograms displayed on screen during offline analysis, and illustrate representative 
examples of the most common types of arrhythmias found during 24 h of monitoring. (A) 
Isolated PVC. (B) PVC in Couplets. (C) PVC in Triplets. (D) NSVT. PVC = premature ventricular 
contractions; NSVT = non-sustained ventricular tachycardia. 
 
 
 
 
 
 
 
 
 
Figure 5. Arrhythmic events detected by 24 h Holter ECG monitoring following IMI with InI 
in rabbits. Total number of Isolated PVC (A), PVC in couplets (B), PVC in triplets, (C) and 
NSVT (D), in untreated rabbits (Normal + IMI) versus Doxorubicin-treated (3 mg/kg/week for 
6 weeks) rabbits (DOX + IMI), after IMI with InI. Mean heart rate (E) and SDNN (F), in rabbits 
from Normal + IMI and DOX + IMI groups after IMI with InI. Data are expressed as mean ± 
SEM. * indicates p < 0.05; and # indicates p < 0.01, comparing Normal + IMI versus DOX + 
IMI groups by t-test. 
 
 
DISCUSSION: 
The primary goal was to develop a minimally-invasive technique that could be used for the 
delivery of stem cells into the myocardium of rabbits (a large sized preclinical animal 
model)17,18, whilst taking advantage of the use of a relatively inexpensive imaging system 
readily available in many clinical and research centers. Here, we show that, using a clinical 
echocardiography system, and aided by InI, a widely available agent, with both in situ 
tracing capabilities and echogenic properties, successful percutaneous contrast 
echocardiography-guided IMI is very effective in delivering injectate to target regions of the 
rabbit heart. As far as we know, this is the first description of a percutaneous contrast 
echocardiography-guided IMI and cell delivery in a large animal model such as the 
rabbit18,19. Whilst InI has been used previously in studies for in situ localization of injectate 
within tissues7,28, this is to our knowledge, the first description of the dual properties of this 
agent as an in vivo ultrasound contrast agent and as an in situ tracer of injectate ex vivo. 
Indeed, complex mixtures of contrast agents and in situ tracing substances previously have 
been described in murine studies aimed at delivering injectates into the myocardium29. 
However, given the echogenic properties of InI and its in situ tracing capabilities, this 
substance could be very useful during competence acquisition whilst undergoing training 
with this technique. 
 
Confirmation of delivery of injectate containing both InI as well as EGFP(+) HEK-293 cells 
using immunohistochemistry demonstrates the applicability of this technique to preclinical 
research aimed at stem cell therapy. An IMI of InI in conjunction with EGFP(+) HEK-293 
resulted in an acute inflammatory response with a predominant neutrophilic infiltrate, 
suggesting a response of acute cellular rejection (within 24 h) to the xenogeneic cells. This 
response probably is not surprising in an immunocompetent animal. On the other hand, an 
IMI with InI alone also elicited an acute inflammatory response (within 24 h) in the treated 
myocardial tissue, which exhibited a predominant macrophage infiltrate. This is in line with 
the observation of acute inflammation described in previous studies following IMI under 
direct view in an open chest procedure4,30-33. Acute inflammation also has been observed 
upon injection of normal saline or PBS solutions into the myocardium34,35, and even into the 
gastrocnemius muscles of the rat36, and therefore this response has been attributed to 
direct tissue injury rather than to the injectate per se.30-32,34-36 Indeed, the International 
Society for Cardiovascular Translational Research acknowledges the common occurrence of 
inflammation in the setting of IMI, but there is no consensus as to whether or not measures 
to reduce this process during the peri-procedural time are useful (e.g., intravenous (I.V.) 
corticosteroids)37. Even though inflammation in this study could also be ascribed to direct 
tissue injury, the results also suggest that InI as a foreign body must also play a role in this 
process, provided a number of macrophages appear to be phagocytizing InI (Figure 3F). A 
thorough analysis of the functional effects of this acute inflammation secondary to IMI 
within the heart, or whether or not these can be ameliorated via administration of 
prophylactic drugs such as corticosteroids is beyond the scope of this manuscript. 
Nevertheless, percutaneous contrast echocardiography-guided IMI to four target regions of 
the myocardium, with a volume of injectate of up to 0.25 mL (1.25 x 106 cells) per IMI site, 
was very well tolerated in the rabbit.  
 
With more than 60 procedures performed to date, and after competency was achieved, the 
mortality secondary to the procedure was very low. For example, no deaths occurred in the 
two cohorts described in step 3.9 (Normal and DOX groups) after IMI. Indeed, to date after 
67 IMI procedures performed as part of an ongoing research program, we have only had 
two deaths directly related to the procedure (2.9% mortality). In one of these, the presence 
of a hemopericardium was demonstrated in the post mortem examination, whilst the other 
developed clinical neurological signs, consistent with acute cerebral ischemia secondary to a 
cardioembolic event, thus requiring a humane end-point. This mortality rate (2.9%) is 
significantly lower than that reported by Lu et al. (11%)8 and Mu et al. (27%)38, in rabbits 
that received IMI under direct view in an open chest procedure. Thus, we consider the 
procedure described in the current study to be safe, and we are using this technique in 
ongoing studies to evaluate stem cell-based therapy in a rabbit model of AICM with 
promising results39,40. 
 
There are several critical points for a successful percutaneous contrast echocardiography-
guided IMI. First, ensure that a parasternal short axis view at the level of the papillary 
muscles is obtained with clear delineation of the endocardial and epicardial contours. Next, 
ensure that the needle tip is within the field of view at all times once this has entered the 
chest cavity and the myocardium to prevent accidental delivery into the pericardial space or 
LV chamber. Then, make sure to keep to a minimum the number of passages through the 
chest cavity, and into the pericardium and myocardium, since this could increase the 
likelihood of local trauma (e.g., laceration) to these structures, and the associated risk of 
hemopericardium. For this, whilst maintaining the needle in the chest cavity (and for some 
target sites, at the same point of entry in the visceral pericardium (e.g., lateral wall)), 
carefully perform subtle changes in the angle of incidence of the needle. Finally, always use 
a needle that has a clear and easy passage through the skin into the chest cavity, thus 
avoiding blunt needle bevels from entering the myocardium and causing significant damage. 
 
The procedure described herein, not only allows reliable and successful delivery of injectate 
to several target sites within the myocardium, but it also permits correction of the needle 
trajectory in real time, thus preventing accidental intrachamber delivery (Figure 2G, H). 
Whilst closed chest IMI procedures have been described previously in mice, there are 
several limitations inherent to this small animal model. These limitations include the 
number of target regions of the myocardium amenable to therapy, and the low 
volume/number of cells that can be injected per target site29,41. In addition, accurate 
delivery of the injectate is often a concern, with a success rate close to 60–70%42, and 
therefore the use of less widely available high frequency ultrasound systems is usually 
required29,41,42. These systems are equipped with linear array transducers that also have 
inherent imaging limitations (e.g., reverberation is a frequent artifact)14. Another limitation 
of small rodent models such as mice and rats, is their intrinsic differences in Ca+2 transport 
system and cellular electrophysiology, which differs from that of humans and large sized 
animal models such as dogs, pigs and rabbits15,16,43. All these limitations often create 
difficulties in translating the findings in these models into the clinic without prior 
confirmation in a large animal model.  
 
Careful monitoring of the animal in the peri-procedural period is mandatory according to 
the contemporary guidelines for the care of laboratory animals. As shown here, this could 
be done by serial echocardiography window scans and ECG tracings, at least until the animal 
is awake from the anesthesia. The acute effects of IMI on heart rhythm also can be 
monitored by 24 h Holter ECG and is our standard practice. Of note, the most frequent 
arrhythmias were isolated PVC, which are relatively benign in nature, and which were more 
common in animals that have been treated with Doxorubicin prior to IMI with InI (see 
Figure 4A and Figure 5A). Other arrhythmias that were relatively less frequent include: PVC 
in couplets; PVC in triplets; as well as NSVT (see Figure 4B–D and Figure 5B–D). However, no 
life threatening arrhythmias such as sustained ventricular tachycardia were observed. Of 
note, we also found that some cardiotoxic manifestations in the DOX group could be 
detected by Holter ECG monitoring, using time frequency-domain variables of heart rate 
variability (HRV) such as SDNN. Thus, a reduced SDNN (Figure 5E, F), a non-linear measure 
of heart health status, was observed in the DOX group compared to the Normal Group. This 
is the first report of reduced HRV, as demonstrated by a reduced SDNN, in the context of a 
rabbit model of AICM, which is in line with the observation that reduced SDNN is a powerful 
independent predictor of cardiac death in patients with HFrEF44-46. The alterations in SDNN 
in the DOX group are probably not related to the IMI procedure itself; nevertheless, 
confirmation of these findings in rabbits receiving Doxorubicin, as well as normal animals 
that do not receive IMI, is required. Whether reduced SDNN in HFrEF could also be 
improved, and therefore used as a surrogate measure of the benefit of stem cell based 
therapy, remains to be evaluated, and will be the focus of the future research. 
 
Several routes of delivery of cells into the heart have been explored, including intravenous, 
intracoronary, and intramyocardial delivery; however, the intramyocardial route as used 
herein, has consistently shown the greatest level of cell retention rates1-5,37. We did not 
assess cell retention rate in the studies presented here, as the methodology used is not 
robust and specific enough to quantitate this in vivo or ex vivo, which is a limitation of this 
study. Instead, we used EGFP(+) HEK-293 cells whose phenotypic characteristics allowed us 
to easily discriminate the presence of these cells within the myocardium, thus indicating 
successful intramyocardial delivery. However, the main aim was to develop a minimally 
invasive technique whereby we could perform IMI and cell delivery into the myocardium of 
a large sized, preclinical model of non-ischemic cardiomyopathy. As demonstrated in Figure 
2 and Figure 3, this was accomplished for the first time by percutaneous contrast 
echocardiography-guided IMI. Further studies are necessary to assess cell retention rate as 
well as any potential beneficial effects of stem cells delivered into the myocardium using the 
procedure described herein; these studies are currently underway. We recently 
communicated promising results in regard to functional effects39,40. 
 
Compared to IMI in an open chest procedure, a percutaneous contrast echocardiography-
guided IMI in a large preclinical model as described in this study, is significantly less invasive 
in nature with quick recovery of the animal following the procedure, and, as mentioned 
above, it also has lower mortality rate8,38. Another approach to IMI is catheter-based IMI, 
which also has been tested in preclinical models and several small clinical trials (for a 
review, see Sheng et al.)47. With this approach, a catheter is advanced into the LV cavity and 
then positioned at target sites within the endocardium. These target sites are either 
identified prior to the procedure, e.g., using contrast cardiac magnetic resonance imaging 
(CMR)48, or during the procedure, e.g., by electromechanical endocardial mapping (EEM), to 
clearly differentiate viable myocardium prior to injection49. This latter approach is less 
invasive compared to open chest IMI under direct view, which is a clear advantage. Also, 
since IHD in humans has a patchy distribution, EEM helps direct the therapy specifically to 
viable sites of the myocardium, which is particularly important in the setting of IHD. 
However, a major drawback is the induction of ventricular arrhythmias, which are a 
common feature of all IMI approaches. Other drawbacks include the lengthy procedural 
time, providing EEM is a highly demanding technique which requires extensive training, and 
an associated risk of cardiac perforation. In contrast, percutaneous contrast 
echocardiography-guided IMI as described in this study, technically is less demanding than 
catheter-based IMI, and, once competency is achieved, it can be performed safely within 25 
min after anesthesia. Similarly, since only a short portion of the needle is advanced into the 
myocardium, there is a lower risk of cardiac perforation, though cardiac laceration is still 
possible.  
 
In conclusion, the percutaneous contrast echocardiography-guided IMI technique described 
in this study in a large animal model, such as the rabbit16,43, is safe, well tolerated, and 
effective in delivering the injectate into the heart. Therefore, it constitutes a promising 
strategy for preclinical hypothesis testing of the effects of cardiac regenerative therapeutics 
in non-ischemic cardiomyopathy (e.g., AICM), including, but not limited to, stem cell-based 
therapy. 
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